The health minister of India has stated that the country will meet its target of supplying over half a billion COVID-19 vaccine doses to states by the end of this month, Reuters news agency reported on Tuesday.
However, not all doses may be administered by then.
The government had told Indias Supreme Court last month that 516 million doses COVID-19 vaccine doses would be made available by end-July 2021, an important milestone for its goal of inoculating all of Indias estimated adult population of 944 million this year.
Daily vaccinations in India touched a national record of 9.2 million doses on 21 June 2021 but have fallen since.
The Indian health ministry stated: "The facts are that a total of more than 516 million vaccine doses will indeed be supplied from Jan 2021 to 31st July 2021. Vaccines are supplied in various schedules throughout a month. Therefore, availability of 516 million doses till end of a particular month does not mean that every dose supplied till that month is going to be consumed/ administered."
The ministry added that 457 million vaccine doses had been dispatched already and 60.3 million more were expected to be sent before the end of this month.
Circio unveils circVec proof-of-concept
GSK releases decade-long data on Shingrix efficacy
BiVictriX receives FDA Orphan Drug Designation for AML treatment candidate
GSK announces positive EAGLE-1 results for gepotidacin in gonorrhoea treatment
Boehringer Ingelheim reports strong growth in 2023 and accelerates late-stage pipeline
Amneal announces launch of PEMRYDI RTU, a ready-to-use oncology injectable
PureTech completes enrollment in Phase 2b ELEVATE IPF trial for LYT-100
GSK's meningitis vaccine candidate accepted for FDA review
Medivir and Vetbiolix report positive results from VBX-1000 Proof-of-Concept clinical study
Norgine submits first marketing authorisation application submissions for approval of eflornithine
Innovent Biologics names new Oncology CMO
UroGen's UGN-103 IND accepted by FDA for bladder cancer treatment
ProAxsis secures GBP1.8m investment
Innate Pharma advances Sanofi-developed NK cell engager to Phase 2 for blood cancer patients